The therapeutic effects of a medicine are overstated in dose-related adverse drug responses. For instance, if a medication to lower high blood pressure lowers blood pressure too much, the patient may have light headedness or dizziness. If insulin or another antidiabetic treatment lowers the blood sugar level too much, a person with diabetes may experience weakness, sweating, nausea, and palpitations. While mostly avoided, this kind of negative medication response can occur. It might happen if a drug dose is too high (overdose response), if the person is exceptionally sensitive to the medicine, or if another drug delays the first drug's metabolism, increasing its level in the blood (see Drug Interactions). Dose-related responses might be significant or not, however they are relatively common. An adverse drug response (ADR) is a medication's unintended, unpleasant side effect that develops during routine therapeutic usage. Adverse medication responses nearly often occur in medical facilities and can have a negative impact on a patient's quality of life, frequently leading to significant morbidity and mortality. Patients who experience adverse medication responses may become dissatisfied with or feel unkind toward their doctors and turn to other forms of self-care, which might lead to the development of more ADRs.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia